Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Efficient and Durable Low-Iridium Catalyst Enabled by a Potential-Triggered Dual-Pathway Mechanism for Acidic Water Oxidation.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

A multidimensional platform to support intestinal epithelial and immune cell co-culture.

Frontiers in nutrition·2026
Same author

Tailoring Avidity through Morphology: Structure-Avidity Relationship in CD38-Binding Nanofiber Radiotracers.

ACS applied bio materials·2026
Same author

On-Resin DIAMSAR-Conjugated CD38-Targeted Peptides and Their Inverso and Dimeric-Inverso Analogs for PET Imaging of Multiple Myeloma.

Bioconjugate chemistry·2026
Same author

Avoidance or Pursuit of Crisis Pregnancy Center Resources Among Abortion-Seeking Clients in Mississippi.

Perspectives on sexual and reproductive health·2026
Same author

Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways.

Communications biology·2026

Related Experiment Video

Updated: Jul 1, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K

Development of New CD38 Targeted Peptides for Cancer Imaging.

Alexander Zheleznyak1, Rui Tang1, Kathleen Duncan1

  • 1Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Molecular Imaging and Biology
|March 14, 2024
PubMed
Summary

Researchers developed novel CD38-targeted radiopharmaceuticals for multiple myeloma (MM) detection. These tracers successfully visualized tumors in preclinical models, showing high specificity and promising potential for clinical translation in MM diagnostics.

Keywords:
CD38Multiple myelomaPeptide bioconjugatePhage displaySmall animal PET

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.0K

Related Experiment Videos

Last Updated: Jul 1, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.0K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Multiple myeloma (MM) diagnosis and staging require specific imaging tools.
  • CD38 is a highly expressed target on MM cells, making it ideal for targeted therapies and diagnostics.
  • Current imaging methods for MM have limitations in specificity and sensitivity.

Purpose of the Study:

  • To develop novel, CD38-targeted small molecule Positron Emission Tomography (PET) radiopharmaceuticals for MM.
  • To evaluate the specificity and efficacy of these tracers in preclinical MM models.
  • To establish a foundation for clinical translation of CD38-targeted PET imaging in MM.

Main Methods:

  • Identification of CD38-specific peptides using phage display and computational algorithms.
  • Synthesis and radiolabeling of peptide bioconjugates with Copper-64 (⁶⁴Cu).
  • In vitro and in vivo evaluation in MM cell lines and murine models, including biodistribution and tumor uptake studies.

Main Results:

  • A lead candidate, ⁶⁴Cu-labeled NODAGA-PEG4-SL022-GGS, demonstrated high binding affinity to CD38+ MM cells.
  • The tracer showed specific tumor uptake in bone marrow and subcutaneous MM models, with rapid clearance from non-target organs.
  • Quantitative PET imaging revealed significantly higher tracer accumulation in tumor-bearing animals compared to controls and scrambled peptide.

Conclusions:

  • Novel CD38-targeted radiolabeled bioconjugates are specific and enable MM visualization.
  • These findings represent a significant step towards clinical translation of PET tracers for MM detection and monitoring.
  • The developed tracers offer potential for improved diagnostic accuracy and treatment response assessment in multiple myeloma.